Bimekizumab significantly improved psoriasis symptoms and health-related quality of life within 4 weeks and sustained benefits through 3 years.
2
In a phase IIIb trial, 743 patients with moderate to severe plaque psoriasis were randomized to receive either bimekizumab or secukinumab.
3
At year 3, 62.2% of continuous bimekizumab patients achieved both PASI score of 0 and DLQI score of 0 or 1, compared to 63.8% of those who switched from secukinumab.
4
Patient-reported outcomes showed higher rates of symptom absence and quality of life improvement in the bimekizumab group compared to the secukinumab group.
5
The study's strengths included a large sample size and low dropout rate, while limitations involved potential biases and restricted generalizability.
